ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
126 hedge funds and large institutions have $1.57B invested in ChemoCentryx, Inc. in 2019 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 38 increasing their positions, 37 reducing their positions, and 17 closing their positions.
557% more capital invested
Capital invested by funds: $239M → $1.57B (+$1.33B)
159% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 17
60% more call options, than puts
Call options by funds: $40.6M | Put options by funds: $25.4M
26% more funds holding
Funds holding: 100 → 126 (+26)
3% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 37
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$56.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$9.34M |
| 5 |
EP
Eversept Partners
New York
|
+$9.01M |
Top Sellers
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$40.6M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$33.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$9.59M |
| 4 |
Renaissance Technologies
New York
|
-$9.26M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$9.01M |
CCXI Hedge Fund Activity: Q4 2019 in Review
126 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q4 2019, worth a combined $1.57B — up 557% from $239M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new CCXI positions and 17 closed out — a net gain of 27 holders — while 38 added to existing stakes and 37 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $56.2M. The largest seller was Carmignac Gestion, cutting an estimated $40.6M.
- 126 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q4 2019, up from 100 in Q3 2019.
- Funds reported $1.57B of ChemoCentryx, Inc. stock for Q4 2019, up 557% quarter-over-quarter.
- 44 funds opened new ChemoCentryx, Inc. positions in Q4 2019 and 17 closed out, a net change of +27 holders.
- The largest ChemoCentryx, Inc. buyer in Q4 2019 was RA Capital Management, an estimated $56.2M added.
- The largest ChemoCentryx, Inc. seller in Q4 2019 was Carmignac Gestion, an estimated $40.6M sold.
Based on aggregated 13F filings for Q4 2019.